Sulzbacher Irene, Birner Peter, Toma Cyril, Wick Nikolaus, Mazal Peter R
Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria.
J Clin Pathol. 2007 Jul;60(7):804-7. doi: 10.1136/jcp.2005.032839. Epub 2006 Oct 3.
To examine the prognostic relevance of c-kit expression in human osteosarcomas and to evaluate the mutation status in exon 9 and exon 11 of the c-kit gene.
c-kit expression was examined in 100 human osteosarcomas by immunohistochemistry using paraffin embedded tumour tissues, and capillary sequencing of genomic DNA was performed to search for mutations in exons 9 and 11 of the c-kit gene.
20 osteosarcomas showed c-kit expression ranging from 5% to 90% (mean 5.9%; SD 16.74%). Furthermore, DNA sequences of exon 9 and exon 11 of the c-kit gene were not altered in these tumours. Overall and disease free survival analysis did not reveal any differences between patients with osteosarcoma with c-kit expression and those with c-kit negative tumours.
C-kit expression is not a prognostic marker in patients with osteosarcoma. The protein expression is not linked to mutations in exon 9 or exon 11 of the c-kit gene. Therefore, these exons may not function as targets for treatment modalities based on the suppression of c-kit tyrosine kinase activity.
研究c-kit表达在人类骨肉瘤中的预后相关性,并评估c-kit基因第9外显子和第11外显子的突变状态。
采用石蜡包埋的肿瘤组织,通过免疫组织化学法检测100例人类骨肉瘤中的c-kit表达,并对基因组DNA进行毛细管测序,以寻找c-kit基因第9外显子和第11外显子中的突变。
20例骨肉瘤显示c-kit表达范围为5%至90%(平均5.9%;标准差16.74%)。此外,这些肿瘤中c-kit基因第9外显子和第11外显子的DNA序列未发生改变。总体生存分析和无病生存分析未显示c-kit表达阳性的骨肉瘤患者与c-kit表达阴性的骨肉瘤患者之间存在任何差异。
c-kit表达不是骨肉瘤患者的预后标志物。蛋白表达与c-kit基因第9外显子或第11外显子的突变无关。因此,这些外显子可能无法作为基于抑制c-kit酪氨酸激酶活性的治疗方式的靶点。